Haemonetics Corporation filed its quarterly report on Form 10-Q for the fiscal quarter ended September 26, 2026, disclosing revenue, earnings, and balance sheet data for the three and six months ended on that date.

Key Highlights

  • Quarterly net revenues of $357,759 thousand for the three months ended September 26, 2026, compared with $327,315 thousand in the prior-year period, according to the filing.
  • Net income of $46,305 thousand for the three months ended September 26, 2026, up from $38,684 thousand in the comparable prior-year quarter.
  • Basic earnings per share of $1.02 and diluted earnings per share of $1.00 for the three months ended September 26, 2026, based on weighted average diluted shares outstanding of 46,463 thousand.
  • Total assets of $2,410,605 thousand as of September 26, 2026, compared with $2,395,925 thousand as of March 28, 2026.
  • Total stockholders' equity of $898,497 thousand as of September 26, 2026, up from $796,320 thousand at fiscal year-end March 28, 2026.
  • 45,537,511 shares of common stock were reported outstanding as of October 30, 2026.

Haemonetics Revenue and Earnings Results for the Quarter Ended September 26, 2026

According to the filing, Haemonetics Corporation (NYSE:HAE), a Boston, Massachusetts-based medical technology company, reported net revenues of $357,759 thousand for the three months ended September 26, 2026, compared with $327,315 thousand for the three months ended September 27, 2025. For the six-month period ended September 26, 2026, net revenues totaled $697,139 thousand, versus $648,709 thousand in the comparable prior-year period. Gross profit for the quarter was $220,913 thousand, compared with $194,744 thousand in the prior-year quarter.

The company reported operating income of $75,120 thousand for the three months ended September 26, 2026, compared with $58,491 thousand in the same prior-year period. Total operating expenses for the quarter were $145,793 thousand, which included research and development costs of $17,029 thousand, selling, general and administrative costs of $118,361 thousand, and amortization of acquired intangible assets of $10,403 thousand. The filing noted no impairment of intangible assets in the current quarter, whereas $8,584 thousand was recorded in the same quarter of the prior year.

On the balance sheet, the filing disclosed cash and cash equivalents of $260,712 thousand as of September 26, 2026, compared with $245,440 thousand as of March 28, 2026. Long-term debt stood at $1,114,118 thousand as of September 26, 2026, down from $1,219,565 thousand at the prior fiscal year-end. Retained earnings increased to $356,961 thousand from $279,344 thousand over the same period. For the six months ended September 26, 2026, net income was $79,315 thousand, compared with $72,715 thousand in the prior-year six-month period.

What Was Disclosed

Haemonetics filed a Form 10-Q for the quarter ended September 26, 2026, covering unaudited condensed consolidated income statements, balance sheets, statements of comprehensive income, stockholders' equity, and cash flows for the three- and six-month periods ending on that date.